Characteristics of severe asthma patients on biologics: a real-life European registry study

Characteristics of severe asthma patients on biologics: a real-life European registry study

Background The use of anti-interleukin-5 (IL5) for severe asthma is based on criteria from randomised controlled trials (RCTs), but in real-life patients might not fulfil the eligibility criteria but may benefit from biologics. We aimed to characterise patients starting anti-IL5(R) in Europe and eva...

Full description

Bibliographic Details
Main Authors: Stefania Principe, Levi B. Richards, Simone Hashimoto, Johannes Anthon Kroes, Job J.M.H. Van Bragt, Susanne J. Vijverberg, Jacob K. Sont, Nicola Scichilone, Kristina Bieksiene, Anneke Ten Brinke, Zsuzsanna Csoma, Barbro Dahlén, Bilun Gemicioglu, Ineta Grisle, Piotr Kuna, Zorica Lazic, Florin Mihaltan, Sanja Popović-Grle, Sabina Škrgat, Alessandro Marcon, Marco Caminati, Ratko Djukanovic, Celeste Porsbjerg, Anke-Hilse Maitland Van Der Zee
Format: Article
Language:English
Published: European Respiratory Society 2023-05-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/9/3/00586-2022.full

Internet

http://openres.ersjournals.com/content/9/3/00586-2022.full

Similar Items